spacer
home > pmps > winter 2002 > formulation integrated device systems for novel enhanced performance products
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulation Integrated Device Systems for Novel Enhanced Performance Products

The aim of developing formulation integrated device systems (FIDS) is to achieve enhanced performance from drugs, using technology that is aimed at solving specific biopharmaceutical, therapeutic, clinical or production problems. These patent-protected high performance systems are designed to provide better treatment outcomes and greater satisfaction for patients, whilst enabling new product development applications and enhanced ‘life cycle management’ opportunities for pharmaceutical companies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor John N Staniforth, Chief Scientific Officer at Vectura Ltd
Professor John N Staniforth PhD MRPharmS FZS CChem FRSC Churchill Fellow, is Chief Scientific Officer of Vectura, a pharmaceutical company specialising in novel pulmonary, oral and dermal technology and new product developments, based in the UK.

John has authored over 200 scientific publications in the area of pharmaceutical technology and is an Honorary Professor of the University of Bath. He is a Non-Executive Director of Penwest Pharmaceuticals Co Inc, New York, and a Founding Director of the drug delivery company, Phoqus Pharmaceuticals Ltd, UK.

spacer
Professor John N Staniforth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement